Sign Up
OverviewAPI
The article delves into gene therapy advancements for treating Primary Immunodeficiencies, focusing on conditions like SCID and hereditary angioedema. It highlights successful trials for ADA-SCID with Strimvelis approval in the EU and ongoing U.S. trials. However, it notes limitations such as specificity and genetic variant transmission risks.

Ask a question